The case for regulating, not banning, kratom
Kratom (Mitragyna speciosa) has become a topic of significant debate among clinicians, policymakers, and the public due to differing views on its safety, pharmacology, and regulatory requirements. A recent article raises important concerns about kratom’s pharmacological actions, potential for addiction, psychiatric risks, and regulatory challenges. Although the goal of protecting public health is admirable, it is crucial that discussions around kratom are rooted in current scientific evidence and avoid …
The case for regulating, not banning, kratom




![Clinicians are failing at value-based care because no one taught them the system [PODCAST]](https://kevinmd.com/wp-content/uploads/bd31ce43-6fb7-4665-a30e-ee0a6b592f4c-190x100.jpeg)









![Silence at the chessboard changed how I talk to patients [PODCAST]](https://kevinmd.com/wp-content/uploads/b664dfaa-d79f-41b8-9445-d43d50340ea4-190x100.png)




